Joshua Lev is recorded as CEO and Board Member at electroCore, Inc. (ECOR) since September 8, 2026 and CFO at electroCore, Inc. (ECOR). electroCore, Inc. reported in an 8-K filed September 9, 2026 that Joshua Lev was appointed member of the Board of Directors, effective September 8, 2026. electroCore, Inc. reported in an 8-K filed September 9, 2026 that Joshua Lev was appointed Co-Chief Executive Officer, effective September 8, 2026. Joshua Lev has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for electroCore, Inc. on June 23, 2026. electroCore, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at electroCore, Inc. includes Daniel S. Goldberger (CEO and Board Member), Joshua S. Lev (CEO, CFO and Board Member), Michael Fox (CEO, COO and Board Member) and 7 others.
“electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026.”
electroCore, Inc. Form 8-K, filed September 9, 2026
· Read the filing
“electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026.”
electroCore, Inc. Form 8-K, filed September 9, 2026
· Read the filing
Joshua Lev on recent calls
“Thank you, and thank you very much for participating in today's iAccess Alpha Virtual Investor Conference. A special thank you to Wiley Johnson for hosting us today.”
“Net sales for the third quarter of 2025 were $8.7 million, an increase of 33% as compared to $6.6 million for the third quarter of 2024. The $2.1 million increase was driven primarily by higher sales of prescription devices and growth in the company's non-prescription general wellness Truvaga product.”
“Net sales for the quarter ended March 31, 2025, were $6.7 million, an increase of 23%, as compared to $5.4 million for the quarter ended March 31, 2024.”
